Previous 10 | Next 10 |
Gainers: Cemtrex (NASDAQ: CETX ) +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...
NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one year If approved, relugolix combination tablet would be the first once-daily, oral treatme...
LONDON and NEW YORK , May 29, 2020 /PRNewswire/ -- Sumitovant Biopharma Ltd. announced that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, today had additio...
Myovant Sciences ( MYOV ) announced additional results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer in an oral presentation at the ASCO20 Virtual Scientific Program. More news on: Myovant Sciences Ltd., Healthcare stocks news, Read mo...
Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program , with simultaneous publication in the New England Journal of Medicine Presentation expands on previous results demonstrating superiority of relugolix to leuprolide acetate, with additional ...
Myovant Sciences (NYSE: MYOV ): Q4 GAAP EPS of -$0.73 beats by $0.04 . More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
- Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected in the second quarter of calendar year 2020 - New Drug Application (NDA) submitted for relugolix monotherapy table...
BASEL, Switzerland, May 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new efficacy and cardiovascular safety data from the Phase 3 HERO study of once-daily, or...
We are all in the gutter, but some of us are looking at the stars. ” - Oscar Wilde The markets have staged a remarkable recovery off COVID-19 meltdown lows here in April. Massive stimulus efforts by the administration and the Federal Reserve, along with some encouraging signs that ...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...